Company: MLTX
Filing Date: 2025-09-29
Form Type: 8-K
Source: 0001213900-25-092614
Chunk: 0

Company: MoonLake Immunotherapeutics
Filing Date: 2025-09-29
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On September 28, 2025, MoonLake Immunotherapeutics
(the “ Company”) issued a press release announcing the week 16 results of the Phase 3 VELA-1 and VELA-2 trials of its registrational
global program in patients with moderate-to-severe hidradenitis suppurativa. The Company will host a webcast today, Monday, September
29, 2025 at 8:00 am, Eastern Time, to discuss the data results.

A copy of the press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial
Statements and Exhibits.